Archive for News Report

After being ditched by Candid, Rallybio finds Avenzo to take its Nasdaq listing

June 1, 2026

Rallybio swerves past Candid pothole to land deal with cancer drug developer Avenzo

June 1, 2026

Crystalys Therapeutics Doses First Patients in New Phase 2 Trial of Dotinurad for Difficult-to-Treat Gout

May 27, 2026

Boehringer pens $478m deal with Immunitas for antibody asset

May 18, 2026

Boehringer furthers inflammatory expansion with €407M biobucks bet on Immunitas asset

May 14, 2026

Evommune bucked biotech IPO drought and is focused on the long game

April 8, 2026